ASCO: PD-L1 Antibody Elicits Durable Response in RCC

Researchers observed durable responses in patients with renal cell carcinoma treated with the PD-L1 antibody MPDL3280A. The study, which was presented at the 2013 ASCO Annual Meeting, was one of the few immune therapy trials that allowed patients with non-clear cell histologies and some clinical activity was observed in these patients.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news